BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1312769)

  • 1. Non-small-cell lung cancer (NSCLC): chemotherapy in advanced disease. Our experience in ten years.
    Gonzalez Baron M; Garcia Giron C; Zamora P; Garcia de Paredes ML; Feliu J; Ordoñez A; Artal A; Garrido P; Chacon JI
    Am J Clin Oncol; 1992 Feb; 15(1):23-8. PubMed ID: 1312769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II trial comparing two chemotherapy combinations for non-small cell lung cancer. Mitomycin, ifosfamide, and cisplatin versus vindesine, ifosfamide, and cisplatin.
    González Barón M; Artal A; Garrido P; García Girón C; Ordóñez A; Feliu J; Berrocal A; Barón JM
    Am J Clin Oncol; 1993 Aug; 16(4):310-4. PubMed ID: 8392287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.
    Chahinian AP; Propert KJ; Ware JH; Zimmer B; Perry MC; Hirsh V; Skarin A; Kopel S; Holland JF; Comis RL
    J Clin Oncol; 1989 Aug; 7(8):993-1002. PubMed ID: 2547030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized comparative trial of sequential versus alternating cyclophosphamide, doxorubicin, and cisplatin and mitomycin, lomustine, and methotrexate in metastatic non-small-cell lung cancer.
    Eagan RT; Frytak S; Richardson RL; Creagan ET; Therneau TM; Coles DT; Jett JR
    J Clin Oncol; 1988 Jan; 6(1):5-8. PubMed ID: 2826714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemotherapy of advanced non-small cell bronchial cancer with mitomycin C/ifosfamide versus mitomycin C/vindesine versus cisplatin/etoposide--a prospective randomized study].
    Gatzemeier U; Heckmayr M; Hossfeld DK; Kaukel E; Koschel G; Neuhauss R
    Pneumologie; 1990 Feb; 44 Suppl 1():258-60. PubMed ID: 2164194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of platinum-based regimens in non-small cell lung cancer. A negative report from the Cuneo Lung Cancer Study Group.
    Buccheri G; Ferrigno D
    Lung Cancer; 1997 Aug; 18(1):57-70. PubMed ID: 9268948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
    Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M
    Cancer; 1990 Apr; 65(8):1692-9. PubMed ID: 2156597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group.
    González Barón M; Feliu J; Espinosa E; García Girón C; Blanco E; Garrido P; Colmenarejo A; Ordóñez A; Moyano A; de la Gándara I
    Ann Oncol; 1994 Apr; 5(4):323-7. PubMed ID: 8075028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
    Bonomi PD; Finkelstein DM; Ruckdeschel JC; Blum RH; Green MD; Mason B; Hahn R; Tormey DC; Harris J; Comis R
    J Clin Oncol; 1989 Nov; 7(11):1602-13. PubMed ID: 2553879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitomycin-C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second-line regimen in lung cancer.
    Chahinian AP; Green G; Holland JF
    Am J Clin Oncol; 1984 Oct; 7(5):419-23. PubMed ID: 6439029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer.
    Buccheri G; Ferrigno D; Rosso A
    Cancer; 1993 Sep; 72(5):1564-72. PubMed ID: 8394198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial with mitomycin-C/ifosfamide versus mitomycin-C/vindesine versus cisplatin/etoposide in advanced non-small-cell lung cancer.
    Gatzemeier U; Heckmayr M; Hossfeld DK; Kaukel E; Koschel G; Neuhauss R
    Am J Clin Oncol; 1991 Oct; 14(5):405-11. PubMed ID: 1659174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
    Ruckdeschel JC; Finkelstein DM; Ettinger DS; Creech RH; Mason BA; Joss RA; Vogl S
    J Clin Oncol; 1986 Jan; 4(1):14-22. PubMed ID: 3510278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European experience with ifosfamide in non-small cell lung cancer.
    Drings P
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):22-30. PubMed ID: 2539645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antineoplastic chemotherapy for bronchial carcinoma].
    Tanneberger S
    Arch Geschwulstforsch; 1985; 55(1):63-71. PubMed ID: 2985017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MACC (methotrexate, doxorubicin, cyclophosphamide and lomustine) versus cis-platinum and etoposide in the treatment of advanced non-small cell lung cancer.
    Buccheri G; Ferrigno D; Curcio A; Vola F; Mattalia E
    Chemioterapia; 1986 Feb; 5(1):53-7. PubMed ID: 3955784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.
    Crino L; Tonato M; Darwish S; Meacci ML; Corgna E; Di Costanzo F; Buzzi F; Fornari G; Santi E; Ballatori E
    Cancer Chemother Pharmacol; 1990; 26(1):52-6. PubMed ID: 2157554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG).
    Buccheri G; Ferrigno D
    Eur J Cancer; 1994; 30A(10):1424-31. PubMed ID: 7833096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapy for small-cell lung cancer: old themes replayed, new ones awaited.
    Viallet J; Ihde DC
    J Clin Oncol; 1989 Aug; 7(8):985-7. PubMed ID: 2547029
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
    Sculier JP; Lafitte JJ; Paesmans M; Thiriaux J; Alexopoulos CG; Baumöhl J; Schmerber J; Koumakis G; Florin MC; Zacharias C; Berghmans T; Mommen P; Ninane V; Klastersky J
    Br J Cancer; 2000 Nov; 83(9):1128-35. PubMed ID: 11027424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.